From: Bisphosphonates and risk of atrial fibrillation: a meta-analysis
Study, year, country | Subjects | Mean age (years) | Mean follow-up (years) | Type of bisphosphonate | AF definition | Total AF events (n) | Variables matched and/or controlled | Quality assessment score§ |
---|---|---|---|---|---|---|---|---|
Bunch and colleagues [15], 2009, USA | 9,623 (98 BIS users and 9,525 non-users) in angiographic research database | 60 | 4.1 | Alendronate Etidronate Ibandronate Risedronate Zoledronic acid | Hospital discharge ICD-9 codes and EKG data | 974 | Age, HTN, hyperlipidemia, DM, HF, CAD, etc | 4/2/3 |
 | 37,485 (7,489 BIS users and 29,996 non-users) in a commercial health care system database | 51 | 4.6 |  |  | 1012 |  |  |
Abrahamsen and colleagues [14], 2009, Denmark | 43,033 patients (14,302 BIS users and 28,731 non-users) with fractures in the National Hospital Discharge register | 74 | 2.7 | Alendronate Clodronate Etidronate Ibandronate Risedronate | Prescription for a cardiac glycoside +/- ICD-10 codes | 797 * | Age, gender, fracture sites, medications use for DM, HTN, hypercholesterolemia, and thrombosis, and Charlson index | 4/2/3 |
Huang and colleagues [17], 2009, Taiwan | 27,257 women (21,037 BIS users and 6,220 raloxifene users) with osteoporosis in the National Health Insurance database | 74 | 0.6 | Alendronate | Inpatient or outpatient ICD-9 codes | 821 | DM, CAD, COPD, history of AF, HTN, and total defined daily dose of drugs | 3/2/2 |